Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 22, 2012, Pages 8710-8715

  Huillard, Emmanuelle ^a,b,d   Hashizume, Rintaro ^a   Phillips, Joanna J ^a,b   Griveau, Amélie ^a,b   Ihrie, Rebecca A ^a,b,e   Aoki, Yasuyuki ^a   Nicolaides, Theodore ^a   Perry, Arie ^a,b   Waldman, Todd ^c   McMahon, Martin ^a   Weiss, William A ^a   Petritsch, Claudia ^a   James, C David ^a   Rowitch, David H ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d SORBONNE UNIVERSITÉ   (France)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Glioma; Protein kinase; Tumor suppressor

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; B RAF KINASE; BRAF V600E KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; UNCLASSIFIED DRUG; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 (5 PIPERAZIN 1 YLPYRIDIN 2 YLAMINO) 8H PYRIDO(2,3 D)PYRIMIDIN 7 ONE; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-(5-PIPERAZIN-1-YLPYRIDIN-2-YLAMINO)-8H-PYRIDO(2,3-D)PYRIMIDIN-7-ONE; BRAF PROTEIN, MOUSE; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASTROCYTOMA; ASTROCYTOMA CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE LOCUS; HUMAN; HUMAN CELL; MALIGNANT ASTROCYTOMA; MONOTHERAPY; MOUSE; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CELL PROLIFERATION; CHILD; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE MUTANT; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; WESTERN BLOTTING;

MURINAE; MUS;

ANIMALS; APOPTOSIS; ASTROCYTOMA; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CHILD; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, NUDE; MICE, SCID; NEURAL STEM CELLS; PHOSPHORYLATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDINES; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861918640     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1117255109     Document Type: Article

References (42)

1. Central Brain Tumor Registry of the United States (2004-2007) Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2007, Statistical Report. Available at http://www.cbtrus.org/reports/ reports.html. Accessed September 11, 2011.
2. Phillips HS, et al.; (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173. (Pubitemid 43357943)
3. Verhaak RG, et al.; Cancer Genome Atlas Research Network (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110.
4. Brennan C, et al. (2009) Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS ONE 4:e7752.
5. Bax DA, et al. (2010) A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin Cancer Res 16:3368-3377.
6. Wu G, et al.; St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44:251-253.
7. Schwartzentruber J, et al. (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226-231.
8. Liang ML, et al. (2008) Tyrosine kinase expression in pediatric high grade astrocytoma. J Neurooncol 87:247-253.
9. Paugh BS, et al. (2010) Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 28:3061-3068.
10. Pollack IF, et al.; Children's Oncology Group (2006) Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: Results from the Children's Cancer Group 945 cohort. J Neurosurg 105(5, Suppl):418-424. (Pubitemid 44954773)
11. Schiffman JD, et al. (2010) Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 70:512-519.
12. Dias-Santagata D, et al. (2011) BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: Diagnostic and therapeutic implications. PLoS ONE 6:e17948.
13. Schindler G, et al. (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121: 397-405.
14. Dankort D, et al. (2007) A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 21:379-384.
15. Corcoran RB, et al. (2010) BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 3:ra84.
16. Dankort D, et al. (2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41:544-552.
17. Charles RP, Iezza G, Amendola E, Dankort D, McMahon M (2011) Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse. Cancer Res 71: 3863-3871.
18. Brenner M, Kisseberth WC, Su Y, Besnard F, Messing A (1994) GFAP promoter directs astrocyte-specific expression in transgenic mice. J Neurosci 14:1030-1037. (Pubitemid 24081901)
19. Bachoo RM, et al. (2002) Epidermal growth factor receptor and Ink4a/Arf: Convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1:269-277. (Pubitemid 41039151)
20. Ligon KL, et al. (2007) Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron 53:503-517. (Pubitemid 46216748)
21. Otero JJ, Rowitch D, Vandenberg S (2010) OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms. J Neurooncol 104:423-438.
22. National Institutes of Health Registry of Clinical Trials Website. Available at http:// clinicaltrials.gov/ct2/results?term=pd-0332991. Accessed August 23, 2011.
23. Smalley KS (2010) PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. Curr Opin Investig Drugs 11:699-706.
24. Davies H, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954. (Pubitemid 34716871)
25. Michaud K, et al. (2010) Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res 70: 3228-3238.
26. Jones DT, et al. (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68:8673-8677.
27. Korshunov A, et al. (2009) Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 118: 401-405.
28. Pfister S, et al. (2008) BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 118:1739-1749. (Pubitemid 351632377)
29. Dhomen N, et al. (2009) Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15:294-303.
30. Garraway LA, et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117-122. (Pubitemid 40966196)
31. Gronych J, et al. (2011) An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. J Clin Invest 121:1344-1348.
32. Robinson JP, et al. (2010) Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. Oncogene 29:335-344.
33. Michaloglou C, et al. (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436:720-724. (Pubitemid 41117276)
34. Raabe EH, et al. (2011) BRAF activation induces transformation and then senescence in human neural stem cells: A pilocytic astrocytoma model. Clin Cancer Res 17: 3590-3599.
35. Zhu J, Woods D, McMahon M, Bishop JM (1998) Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 12:2997-3007. (Pubitemid 28469302)
36. Dougherty MJ, et al. (2010) Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro-oncol 12:621-630, 10.1093/neuonc/noq007.
37. Forshew T, et al. (2009) Activation of the ERK/MAPK pathway: A signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 218:172-181.
38. Weber RG, et al. (2007) Frequent loss of chromosome 9, homozygous CDKN2A/p14 (ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas. Oncogene 26:1088-1097.
39. Nicolaides TP, et al. (2011) Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res 17:7595-7604.
40. Knobbe CB, Reifenberger J, Reifenberger G (2004) Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol 108: 467-470. (Pubitemid 39534587)
41. Günther HS, et al. (2008) Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 27: 2897-2909. (Pubitemid 351620450)
42. Hashizume R, et al. (2010) Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing. Neuro-oncol 12:366-376.